Follow Eli Lilly to never miss an important update.
The US Food and Drug Administration (FDA) has approved a new drug combination for patients with advanced breast cancer. This treatment is designed for cases where the cancer has spread beyond the original site, providing a new option for a difficult-to-treat patient group.
While weight-loss drugs are the main driver of growth for the company right now, this approval is a reminder of its deep pipeline in other areas like oncology. Expanding its cancer portfolio helps diversify the business and ensures it is not relying on a single category for its future revenue.
Source: Reuters
Guggenheim set its price target for the drugmaker at $1,284. This is slightly lower than the average target of $1,343 across all Wall Street firms that follow the company. While the firm sees room for the stock to grow, its target is more conservative than many of its peers. This move comes as the company continues to ramp up production of its weight-loss treatments to meet high demand.
Source: Guggenheim
Regulators in Ohio are working to curb the supply of unapproved, bootleg versions of an experimental drug from Eli Lilly. These copycat versions have appeared on the market before the official treatment has finished the testing and approval process.
This is a risk to watch because unapproved versions can lead to safety issues that might unfairly damage the reputation of the real drug. It also shows the extreme demand for the company's new treatments, which often exceeds what the company can currently produce.
Source: WSJ
Berenberg Bank set its price target for the stock at $1,400. This is higher than the average analyst target of about $1,342. Since this is a new target without a rating change from a smaller firm, it is a routine update rather than a major shift in how the market sees the company.
Source: Berenberg Bank
Eli Lilly reported that its oral weight-loss drug, Foundayo, now accounts for more than 30 percent of new patients in the U.S. market. This allows the company to close the gap with its main rival, Novo Nordisk, which had an early lead with its own pill version of Wegovy.
This shift matters because pills are easier to make and ship than weekly injections. For a company like Lilly that has struggled to build enough factory space to meet demand, moving patients to oral treatments simplifies the supply chain and helps reach more people. It also carries higher profit margins, making this rapid market share gain a key indicator of the company's future earnings power.
Source: Reuters
Management is consistently underestimating its own growth, as the business is outrunning even the most bullish forecasts. You can trust their outlook as a floor, but the real results usually land much higher.
| Expectation | |
|---|---|
| EPS | $9.87 |
| Revenue | $22.19B |